ARCA Biopharma Inc (ABIO) Peer Comparison

$2.48

$-27.52 (-91.73%)

As on 30-Aug-2024 19:22EDT

Market cap

$35 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.1

Div. Yield

0 %

Edit

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Market cap ($ Mln)	35	10
Revenue ($ Mln)	0	22
Net Profit ($ Mln)	-7.20	-15.86
Net Margin (%)	-4,090.91	-73.52
RoE (%)	-20.69	--
Price to Earnings	--	--
Price-To-Book	1.07	1.79

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Operating Revenue	0.18	21.57
Cost of Revenue	0.08	7.84
Gross Profit	-0.11	10.62
Operating Expenses	8.73	27.28
Operating Profit (EBIT)	-8.76	-13.56
Other Income	0.00	0.00
Profit before Tax	-7.20	-15.86
Provision for Tax	0.95	0.39
Profit after Tax (Net Income)	-7.20	-15.86
Minority Interest	0.00	0.00
Consolidated Profit	-1.42	-0.80

Liabilities ($ Mln)

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Shareholder's Funds	32.57	-21.91
Minority Interest	0.00	0.00
Non-Current Liabilities	0.00	10.65
Current Liabilities	1.27	26.23
Total Liabilities	37.86	10.26

Assets ($ Mln)

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Non-Current Assets	0.02	0.52
Current Assets	33.82	14.44
Total Assets	37.86	10.26
Total Debt*	0.02	0.29
Net Current Assets	32.55	-11.79

Cashflow ($ Mln)

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Cash From Operating Activities	-5.01	-9.58
Cash Flow from Investing Activities	--	--
Cash from Financing Activities	--	6.89
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
ROCE (%)	-13.47	165.50
ROE (%)	-20.69	132.32
ROA (%)	-18.51	-45.92
EBIT Margin (%)	-4,994.89	-33.51
Net Margin (%)	-4,090.91	-73.52
Cash Profit Margin (%)	-0.05	0.00

Growth Ratios

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Revenue Growth (%)	--	32.21
EBIT Growth (%)	-11.31	72.24
Net Profit Growth (%)	-51.01	62.90
EPS Growth (%)	--	93.78
Book Value Growth (%)	--	53.34

Valuation Ratios

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Price / Earnings	--	-0.40
Price / Book Value	--	-0.35
Dividend Yield (%)	--	--
EV/EBITDA	5.09	-0.27
Market Cap ($ Cr)	--	--

Solvency Ratios

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.00	-0.01
Current Ratio	26.61	0.55
Quick Ratio	26.61	0.33
Interest Coverage	-15.00	-18.08

Operating Efficiency Ratios

	ARCA Biopharma Inc (ABIO)	Agile Therapeutics (AGRX)
Debtors to sales (%)	0.00	21.10
Asset Turnover	0.00	0.62
Receivable days	--	63.09
Inventory Days	--	82.79
Payable days	1,145.11	352.07
Cash Conversion Cycle	--	-206.19

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly